Drug intelligence / Profile preview

azithromycin + fluconazole + secnidazole

Development stage
Unknown
Lead developer
Calibar Pharmaceuticals
Modality
Small Molecules
Administration
Oral
01

Overview

AZIBER-SF KIT is a combination drug product developed and marketed by Calibar Pharmaceuticals, primarily used for the syndromic management of vaginal discharge and pelvic inflammatory disease (PID). The kit contains three distinct active pharmaceutical ingredients: azithromycin, fluconazole, and secnidazole. Azithromycin is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Fluconazole is an azole antifungal agent that targets the fungal enzyme lanosterol 14-alpha-demethylase, thereby disrupting the synthesis of ergosterol, an essential component of fungal cell membranes. Secnidazole is a nitroimidazole anti-infective effective against anaerobic bacteria and protozoa; it is reduced within the target organism to reactive intermediates that cause DNA strand breakage. This combination is designed to provide broad-spectrum coverage against common pathogens involved in reproductive tract infections, including *Chlamydia trachomatis*, *Neisseria gonorrhoeae*, *Candida* species, *Trichomonas vaginalis*, and various anaerobic bacteria associated with bacterial vaginosis.

Brand names
AZIBER-SF KIT
Other names
azithromycin + fluconazole + secnidazoleSF KitCombikit of Azithromycin, Fluconazole and Secnidazole
02

Targets

CYP51A1 (Sterol 14α-demethylase)NeuraminidaseBacterial 50S ribosomal subunit

Beyond the preview

Go deeper on azithromycin + fluconazole + secnidazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on azithromycin + fluconazole + secnidazole.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call